Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Tests of `superior' Aids vaccine open

Friday 17 October 1997 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

American researchers said yesterday they were starting tests of a new vaccine against the Aids virus in people and said this one was far superior to earlier failed efforts.

Julia Hurwitz and Karen Slobod of St. Jude Children's Research Hospital in Memphis, Tennessee, said the US Food and Drug Administration (FDA) had given them the go-ahead to start safety trials in human volunteers. They said their vaccine, which uses part of the protein coating of the human immunodeficiency virus (HIV), was meant to protect healthy people against infection and not to help those already infected.

"The whole point of the vaccine is to alert the immune system against a pathogen that may appear in the future," Hurwitz said. "If we can wake them up by showing them the shape of a foreign agent before it comes along, then they can block that agent."

They said they would be recruiting between nine and 18 healthy volunteers for the Phase I clinical trial, which focuses on safety alone and not on whether the vaccine works.

The St Jude vaccine uses outer protein layers known as envelopes from 23 different mutations of HIV, each contained in a smallpox vaccine.

"Our concern is that HIV is a master of disguises. One HIV may have an envelope that looks like a circle. Another may have one that looks like a square, another like a triangle and so on," Ms Hurwitz said.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in